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The Ob protein (leptin) and the kidney. Mutation of the Ob gene, which
encodes for leptin, or mutation of the leptin receptor leads to obesity in
mice. Humans, for the most part, have a positive correlation of leptin with
body fat mass suggesting possible defects in leptin effector mechanisms
that may contribute to obesity. As patients on hemodialysis have difficulty
with appetite, we investigated whether leptin is cleared by the kidney and
is elevated in hemodialysis patients. In patients with intact renal function
there was a net renal uptake of 12% of circulating leptin, whereas in
patients with renal insufficiency there was no renal uptake of leptin. In a
separate cohort of 36 patients with end-stage renal disease (ESRD),
peripheral leptin levels factored for body mass index was increased by
fourfold as compared to a group of healthy controls (N 5 338). The leptin
receptor exists in a long and short form, with the long form primarily
expressed in the hypothalamus but also in the lungs and kidneys of the
mouse. Further studies are necessary to clarify the role of leptin in
regulating appetite in patients with ESRD and the role of leptin in directly
affecting kidney function via its receptors.
The prevalence of obesity has increased dramatically in the
United States during the past decade. The recent National Health
and Nutrition Examination Survey (NHANES) reported that the
prevalence of overweight Caucasian men and women increased
from 20% to 30% in the past decade [1]. In African American
men and women the prevalence of obesity has increased from 30
to 40% in men and 30% to 48% in women. Hispanic Americans
had a similar increase in the prevalence of obesity. The estimated
cost of treating obesity and its complications is estimated to be 68
billion dollars annually. The increased prevalence of obesity
contributes to the development of NIDDM and hypertension and
thus will promote increased prevalence and progression of kidney
disease [2]. Several excellent reviews discuss the pathogenesis of
obesity in humans [3] and the molecular genetics of obesity [4].
The present review will highlight the identification of two pro-
teins, leptin and its receptor, that cause obesity in mice and then
focus on the relationship of these two proteins with the kidney.
IDENTIFICATION OF LEPTIN AND THE LEPTIN
RECEPTOR
The identification of the genes responsible for obesity in two
strains of mice has recently been elucidated and allows for analysis
of these genes in the human population. The identification has
also led to novel concepts in how the body deals with disturbances
in energy balance.
The ob/ob mouse is characterized by hyperphagia, decreased
energy expenditure, reproductive deficiency, NIDDM with hyper-
insulinemia and onset of obesity by three to four weeks of age.
Parabiosis experiments performed in 1959 with normal mice
sharing the circulation of ob/ob mice resulted in the ob/ob mouse
losing weight and reducing its appetite, whereas there was no
effect on the normal mouse [5]. This suggested that the ob/ob
mouse was missing a circulating factor that controls appetite and
weight. The ob/ob gene was identified in 1994 by Zhang et al by
positional cloning [6]. The gene was found to encode a secreted
167 amino acid protein named leptin. Mutations were found in
codon 105 leading to a defective leptin protein and in the
promoter leading to absence of leptin mRNA synthesis in two
different strains of ob/ob mice, respectively. Administration of
leptin resulted in weight loss, increased locomotor activity and
improved insulin and glucose levels [7–9].
The db/db mouse has a phenotype identical to the ob/ob mouse.
However, in parabiosis experiments between normal mice and
db/db mice, the normal mouse stopped eating and lost weight
whereas the db/db mouse was not affected [10]. This and other
data were interpreted to suggest that the db/db mouse had a
defective response to a circulating factor that controls appetite.
Upon the identification of leptin, it was found that the db/db
mouse was markedly hyperleptinemic and it was reasoned that
this mouse had a defect in the leptin receptor [11]. This was
indeed the case. Tartaglia et al isolated the db gene by assaying
expression libraries for CNS receptors demonstrating strong
affinity for leptin [12]. A loss of function mutation was identified
in db/db mice that prevents expression of the 302 amino acid
cytoplasmic domain of the leptin receptor which contains con-
served signaling motifs for Janus protein tyrosine kinase (Jak),
and signal transducers and activators of transcription (STAT)
binding.
FUNCTION OF LEPTIN AND ITS RECEPTORS
The pathway by which leptin regulates energy balance is
outlined in Figure 1. Increased caloric intake coupled with
decreased caloric expenditure will lead to an expansion of the
adipocyte size. This, in some not yet understood way, signals the
adipocyte to increase leptin synthesis and release. Leptin enters
the circulation, binds to leptin-binding proteins, and is ultimately
transported into the cerebrospinal fluid by receptors located on
the choroid plexus. Within the hypothalamus, leptin binding to its
receptor activates the Jak/STAT signal cascade to activate or
Key words: obesity, hemodialysis, end stage renal failure, progression of
renal disease, leptin.
© 1998 by the International Society of Nephrology
Kidney International, Vol. 53 (1998), pp. 1483–1487
1483
deactivate genes. A major action of leptin on the hypothalamus is
to decrease production of neuropeptide Y (NPY) [13]. A reduc-
tion in NPY leads to a decrease in appetite and increased energy
expenditure, ultimately resulting in weight loss [14].
In general, the circulating leptin concentration is in proportion
to the amount of adipose tissue, although absolute levels may be
modified by factors such as gender [3, 15]. Changes in adipose
tissue mass result in concomitant changes in leptin. Weight loss
results in a decrease in leptin and weight gain significantly
increases circulating leptin in both humans and rodents [15–18].
In addition, leptin is altered by extremes in energy intake. Serum
leptin falls dramatically with short term fasting and is increased
40% by massive overfeeding in humans [17, 19]. Fasting and
overfeeding have similar effects on circulating leptin in rodents
[18, 20]. However, rodents and humans differ in the leptin
response to normal meal intake. Leptin levels do not change
acutely following normal meal consumption in humans [15, 20] in
contrast to the rapid rise following food intake in rodents [21].
Leptin synthesis is also regulated by several hormones and
pharmacologic agents. Insulin and dexamethasone stimulate lep-
tin whereas b-adrenergic agonists and testosterone inhibit leptin
production [reviewed in greater detail in 13, 14].
The leptin receptor belongs to the class I cytokine receptor
family [12]. Five isoforms have been identified [12, 22]; The two
major isoforms, Ob-Ra and Ob-Rb, are illustrated in Fig. 2.
Observed in all leptin receptor isoforms are the extracellular
binding domain consisting of 840 amino acids and the transmem-
brane region of 34 amino acids. The intracellular domain is
variable. Ob-Rb, the long leptin receptor, has a 302 amino acid
intracellular domain which contains interaction sites for Jak
kinase and STAT proteins, that are characteristic second messen-
gers for cytokine receptor signaling. Ob-Ra, the short leptin
receptor, has a 34-aa intracellular domain that retains the Jak
binding site but not the STAT site. This receptor is present in
almost all tissues examined and it is unknown if it retains
functional signaling activity. Large amounts of Ob-Ra are present
at the choroid plexus where it acts as a transporter for leptin to
cross the blood-brain barrier. One other leptin receptor Ob-Re,
lacks a transmembrane domain and thus may function as soluble
receptor/binding protein. Leptin is present in the circulation in
both bound and free forms. In lean individuals up to 50% of leptin
is present in the bound form whereas in obese individuals the
majority of leptin is in the free form [23]. This may be due to a
limited concentration of leptin binding proteins in the circulation
that does not vary with increasing leptin production. The physio-
logic significance of bound versus free leptin is unknown.
Although leptin deficiency leads to obesity in the ob/ob mouse,
this is not the case for human obesity. In adults, children, and
infants leptin levels are highly correlated with the fat mass [15].
Furthermore, no deleterious mutations in the human leptin
receptor have yet been identified [24]. However, of great interest
is the recent identification of two related youngsters who mani-
fested severe obesity during their infant years [25]. Both children
had normal birth weights (50th percentile) but developed severe
intractable obesity by the age of two years with weights twice as
great as the 98th percentile. One child required liposuction of
lower limb fat in an attempt to improve mobility. A frame-shift
mutation was found in their leptin gene which led to a truncated
form of the protein that was not secreted by the adipocyte. It
remains to be seen whether these individuals respond to exoge-
nous leptin administration. Thus, it is believed that certain rare
obesity syndromes that are characterized by the development of
obesity at a very early age of onset may be linked to defects in
leptin or its receptor. However, in the vast majority of adult-onset
obesity it is unlikely that defects in the leptin pathway are solely
responsible.
In chronic end-stage renal disease, a major issue is not obesity
and enhanced appetite but the reverse. Patients often have
Fig. 1. Pathway by which leptin inhibits
appetite. Leptin is secreted by adipocytes and
interacts with its signaling receptor in the
hypothalamus to decrease production of
neuropeptide Y. Inhibition of neuropeptide Y
decreases hunger, increases activity, and
thermogenesis.
Fig. 2. Leptin receptors. The long receptor of leptin (OB-Rb) contains an
intracellular domain that has a consensus Jak binding site (black segment)
and a STAT binding site (hatched segment). The short leptin receptor
(OB-Ra) retains the intracellular Jak binding site, however, the STAT
binding site is missing.
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anorexia and weight loss that is correlated with significant mor-
bidity and mortality. Several studies have demonstrated that
decreased albumin and low protein intake is associated with
increased mortality despite adequate dialysis [26–28]. With these
issues in mind, several studies have examined the role of the
kidney in clearing leptin and have measured leptin levels in
patients with end-stage renal failure.
LEPTIN CLEARANCE BY THE KIDNEY
We postulated that clearance of leptin may be via the kidney in
humans. As the leptin molecule is 14 to 16 kDa, it would likely be
filtered at the glomerulus. To evaluate the role of the kidney in
clearance of circulating leptin, we measured levels of leptin in
aortic and renal vein plasma from patients with varying degrees of
renal function, who were undergoing elective cardiac catheteriza-
tion. We found a 12% decrease of leptin levels across the kidney
bed (aortic leptin, 7.91 6 1.4 vs. renal vein leptin, 7.02 6 1.3; P ,
0.005), in adults with intact renal function [29]. Simultaneous
measurement of the difference in leptin concentration across the
kidney and the renal plasma flow rate enabled the net renal
extraction rate to be calculated. There was a mean net renal
extraction of 480 ng/min in the 8 patients evaluated. In patients
with moderate renal insufficiency (creatinine 2.5 mg/dl; N 5 5),
there was no clearance of leptin across the kidney vascular bed.
Urinary levels of leptin were below the detection of our assay,
suggesting that leptin was being degraded in the kidney. In
support of our findings that the kidney plays a major role in
clearing leptin, a recent report of 57 NIDDM patients evaluating
determinants of plasma leptin levels [30] using multiple regression
analyses found a significant positive correlation between plasma
circulating leptin levels and the serum creatinine.
Administration of radio-labeled leptin to rats that had under-
gone bilateral nephrectomy, reduced leptin clearance to 19% of
control values [31]. In a separate study by the same investigators,
arteriovenous measurement of leptin across the kidney showed a
decrease of 25% of circulating endogenous leptin in rats with
normal renal function [32]. In addition, leptin was not found in the
urine and no leptin metabolites were found in the renal vein,
suggesting that leptin was filtered at the glomerulus and likely
taken up by proximal tubular cells. Whole body clearance of
radiolabeled leptin was estimated at 5.4 ml/min/kg, which was only
slightly higher than renal clearance of leptin (5.3 ml/min/kg),
indicating that the kidneys account for almost 100% of whole
body clearance of leptin. These studies were performed in the
fa/fa rats which have a mutation in the long form of the leptin
receptor, thus excluding this receptor as playing a major role in
renal clearance of leptin. Hence, in both rats and humans, it
appears that the kidney is a major site of leptin clearance.
LEPTIN ACCUMULATION IN END-STAGE RENAL
FAILURE
If leptin is primarily cleared by the human kidney, it follows that
leptin levels would be elevated in patients with end-stage renal
disease (ESRD). Several studies have found such a relationship.
In our study of 37 chronic hemodialysis patients, pre-dialysis
plasma leptin levels were elevated fourfold as compared to a
group of 331 healthy controls (37.6 6 10.6 ng/ml vs. 8.25 6 7.25
ng/ml, respectively; P , 0.01) [29]. When corrected for body mass
index (BMI), the relationship persisted (1.30 6 0.32 vs. 0.29 6
0.01, respectively; P , 0.005). Very similar results were obtained
in an independent study of 141 ESRD patients [33]. Mean values
in patients with ESRD of both sexes (males, 26.8 6 5.7 ng/ml and
females, 38.3 6 5.6) were significantly higher (P , 0.001) than
those obtained in normal volunteers, (normal males, 11.9 6 3.1
ng/ml and normal females, 21.2 6 3.0 ng/ml). A separate study
found that both hemodialysis and peritoneal dialysis patients had
elevated leptin levels [34]. Measurement of pre- and post-hemo-
dialysis levels of leptin failed to demonstrate significant clearance
of leptin during hemodialysis with a conventional modified cu-
prophane membrane [29].
The above studies also demonstrated that circulating leptin in
hemodialysis patients primarily existed in the free form, not
bound to leptin-binding proteins [29, 34], and was of the same
molecular weight as intact leptin [33]. Thus, there does not appear
to be an increase in leptin binding proteins nor of leptin degra-
dation products in ESRD patients.
Does “hyperleptinemia” inhibit appetite in patients with renal
failure? The answer to this question is not yet known. We found
that in our population that leptin levels correlated well with the
BMI, although with higher levels than in patients without renal
failure. The rate of increase of leptin with BMI was also found to
be significantly greater among patients with ESRD as compared
to controls in two separate studies [33, 34]. Leptin levels do not
appear to correlate with recent changes in weight nor adequacy of
dialysis [33]. It thus appears that patients with renal failure have
re-adjusted their “leptin-stat,” and despite high levels of leptin,
continue to have a correlation with their BMI. It is possible that
due to hyperleptinemia, dialysis patients have less caloric intake at
the same BMI than non-dialysis patients; however, this remains to
be determined.
Based on data that relatively large doses of leptin had to be
administered to curtail appetite and induce weight reduction in
normal mice [9], it is conceivable that patients with markedly high
leptin levels may manifest a relationship between leptin levels and
parameters of appetite and nutrition. Interestingly, we found that
5% of our dialysis population had extraordinarily high leptin
levels (.200 ng/ml) that could not be explained purely on the
degree of their fat mass [29]. These patients were not on
corticosteroids, which may stimulate leptin production directly.
We are presently following these patients to determine if serial
leptin levels correlate with disturbances in appetite over time.
EFFECTS OF LEPTIN ON THE KIDNEY
It is interesting to note that the kidney is one of the few
extra-neural tissues that express the long-form of the leptin
receptor. Northern analysis demonstrates the long form of the
leptin receptor mRNA (Ob-Rb) in mouse kidney and lung, but
not in heart, spleen, liver, skeletal muscle, or testis [35]. Utilizing
reverse transcriptase-polymerase chain reaction (RT-PCR), with
specific primers for Ob-Rb, a separate study found expression
only in mouse kidney and adrenal gland among peripheral tissues
examined [36]. In situ analysis with a labeled cDNA probe
detected Ob-Rb primarily in the medulla of mouse kidney [36].
Hybridization with {125I}-leptin of rat kidney found absence of
labeling in the cortex; however, there was intense labeling of
vascular structures and medullary sites [37]. The functional role of
leptin binding sites and leptin receptors in the kidney are un-
known.
The effects of leptin on kidney function in rats has been studied
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by several groups. Intravenous administration of leptin for five
days to normal rats stimulated a diuresis with urine volumes being
twice normal [37]. Administration of leptin directly into the renal
artery stimulated a natriuresis but not a kaliuresis suggesting an
effect of leptin at the level of the collecting tubule [38]. However,
blood pressure was not affected in either study. Sympathetic nerve
inflow to the kidney was found to be markedly stimulated by leptin
administration [39]. It is possible that leptin has opposing effects
on blood pressure by its ability to enhance sympathetic tone to
increase blood pressure and promote a natriuresis to lower blood
pressure. Other effects of leptin on the kidney remain to be
evaluated. Given that the leptin receptor belongs to the class I
family of cytokine receptors, the action of leptin may be important
in inflammatory disorders of the kidney.
The growing study of leptin encompasses many fields including
nephrology. Apart from its possible role in appetite regulation in
patients with renal insufficiency, it is likely that there are other
relationships between leptin and the kidney. The presence of the
long form of the leptin receptor in the kidney makes this organ a
prime site by which leptin may exert peripheral effects. Studies to
evaluate the localization of the leptin receptor in the kidney, a
characterization of its signaling pathways in renal cells, and
physiologic and pathophysiologic consequences of leptin action
on the kidney are intriguing future areas of study that will increase
our understanding of this recently discovered hormone.
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